PharmaCyte Biotech ( (PMCB) ) has released a notification of late filing.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PharmaCyte Biotech, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending October 31, 2025. The company cites the need for additional time to prepare and review its financial statements to ensure comprehensive disclosure as the primary reason for the delay. This delay could not be avoided without unreasonable effort and expense. The company anticipates filing the report no later than five calendar days after the original due date of December 15, 2025. Notably, PharmaCyte Biotech does not expect any significant changes in its financial results compared to the same period last year. The notification was signed by Joshua N. Silverman, the CEO and President, who assured stakeholders of ongoing compliance efforts.
More about PharmaCyte Biotech
Average Trading Volume: 3,292,617
Technical Sentiment Signal: Sell
Current Market Cap: $6.93M
Learn more about PMCB stock on TipRanks’ Stock Analysis page.